top of page

Thank you for submitting your Paper of the Quarter application. Your submission is summarised below.

Quarter

Q2, 2024

Applicant

Dirk Nettelbeck

Paper Title

Test

The name(s) of the first, last or corresponding authors who are DG-GT members

Dirk Nettelbeck

Paper Link / Upload

Date of the online publication

1 July 2024

Summary

Cancer therapeutics approved for clinical application include oncolytic viruses and antibodies, which evolved by nature, but were improved by molecular engineering. Both facilitate outstanding tumor selectivity and pleiotropic activities, but also face challenges, such as tumor heterogeneity and limited tumor penetration. An innovative strategy to address these challenges combines both agents in a single, multitasking therapeutic, i.e., an oncolytic virus engineered to express therapeutic antibodies. Such viro-antibody therapies genetically deliver antibodies to tumors from amplified virus genomes, thereby complementing viral oncolysis with antibody-defined therapeutic action. Here, we review the strategies of viro-antibody therapy that have been pursued exploiting diverse virus platforms, antibody formats, and antibody-mediated modes of action. We provide a comprehensive overview of reported antibody-encoding oncolytic viruses and highlight the achievements of 13 years of viro-antibody research.

X / Twitter handles of your institution, lab or individual researchers

bottom of page